All In Biotech

NDA 021648 · Hikma

Digoxin

Digoxin · Oral · Cardiac Glycoside

Last checked: Nov 20, 2026Latest source record: Apr 14, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2004

Aug 26, 2004

Approved uses

1

Original approval plus efficacy supplements

Registered trials

275

14 Phase 3, 12 recruiting

FAERS reports

62,828

52,124 serious, 12,311 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Dec 11, 2025.

In adults, digoxin is indicated for the treatment of mild to moderate heart failure and for the control of resting ventricular rate in patients with chronic atrial fibrillation. (1) In pediatric patients with heart failure, digoxin increases myocardial contractility. 1.1 Heart Failure Digoxin Oral Solution, USP is indicated for the treatment of mild to moderate heart failure. Digoxin increases left ventricular ejection fraction and improves heart failure symptoms as evidenced by increased exercise capacity and decreased heart failure-related hospitalizations and emergency care, while having no effect on mortality. Where possible, digoxin should be used with a diuretic and an angiotensin-converting enzyme inhibitor, but an optimal order for starting these three drugs cannot be specified. 1.2 Heart Failure in Pediatric Patients Digoxin increases myocardial contractility in pediatric patients with heart failure. 1.3 Atrial Fibrillation in Adults Digoxin Oral Solution, USP is indicated for the control of resting ventricular response rate in patients with chronic atrial fibrillation. Digoxin should not be used for the treatment of multifocal atrial tachycardia.

Mechanism: All of digoxin’s actions are mediated through its effects on NaK–ATPase. This enzyme, the “sodium pump,” is responsible for maintaining the intracellular milieu throughout the body by moving sodium ions out of and potassium ions into cells. By inhibiting NaK–ATPase, digoxin causes increased availability of intracellular calcium in the myocardium and conduction system, with consequent increased inotropy, increased automaticity, and reduced conduction velocity; indirectly causes parasympathetic stimulation of the autonomic nervous system, with consequent effects on the sino-atrial (SA) and...

Therapeutic areas: Cardiovascular and metabolic

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 26, 2004 Original approval · Type 7 - Drug Already Marketed without Approved NDA LabelReviewLetter
1 products under this application
  • DIGOXIN · DIGOXIN 0.05MG/ML · ELIXIR, ORAL · Prescription · TE AA

Clinical trials

Interventional ClinicalTrials.gov studies with "Digoxin" as an intervention, any sponsor and status, largest first.

All 275 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dyspnoea5,634
  • nausea4,389
  • dizziness4,165
  • fatigue3,918
  • atrial fibrillation3,649
  • diarrhoea3,506
  • asthenia3,153
  • vomiting3,087
  • death3,063
  • hypotension2,926
  • pain2,780
  • fall2,659

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041,977
20051,966
20061,914
20071,652
20084,059
20093,129
20102,884
20113,444
20123,505
20132,894
20143,567
20153,831
20163,844
20173,589
20183,457
20192,941
20202,712
20212,113
20221,733
20232,175
20242,038
20251,994
20261,403

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Digoxin* (Digoxin)

2024 spending

$36.9M

Beneficiaries

370,872

1,579,920 claims

Per beneficiary

$99

$0.43 per unit

View as table
YearSpending
2020$71,931,518
2021$66,396,304
2022$57,606,557
2023$49,736,784
2024$36,860,211

Part B: Digoxin* (Digoxin*) · HCPCS J1160

2024 spending

$302

Beneficiaries

22

25 claims

Per beneficiary

$14

2024 ASP limit $10.34 per unit

View as table
YearSpending
2020$309
2021$251
2022$416
2023$236
2024$302

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,258 on PubMed

Sponsor: Hikma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.